The Food and Drug Administration has closed its enforcement action against wearable device maker Whoop, marking a significant shift in how the agency approaches blood pressure monitoring in consumer health trackers. The FDA issued a closeout letter Tuesday indicating it will not enforce device requirements against the modified version of Whoop’s blood pressure feature, a reversal from its July warning letter that initially challenged the feature as an unregulated medical device.
The resolution reflects a broader policy change the FDA announced in January guidance, which concluded that blood pressure measurements do not require medical device oversight when used for wellness purposes rather than diagnosis. Whoop’s response demonstrates how companies navigate regulatory ambiguity and the practical limits of FDA enforcement when technology outpaces existing guidance.
How The Dispute Began And What Changed
When the FDA sent its initial warning letter to Whoop in July, regulators stated that blood pressure inherently relates to medical diagnosis and therefore qualified as a medical device subject to premarket review and quality standards. The assertion sparked debate among medtech experts about whether consumer-grade blood pressure estimates should face the same scrutiny as clinical devices used in hospitals and physician offices.
Whoop had launched its blood pressure insights feature in 2024, providing daily systolic and diastolic blood pressure estimates derived from heart rate and blood flow patterns during sleep. The company argued the feature served wellness purposes and defended its scientific validity against the warning letter, even as some observers predicted the FDA would hold firm on device classification.
Between receiving the warning and the closeout letter, Whoop made specific modifications to address FDA concerns. The company adjusted dial boundaries and interface language to prevent users from interpreting the feature as a clinical diagnosis tool. A Whoop spokesperson confirmed in writing that these changes removed any confusion suggesting the feature classified blood pressure in a clinical manner, which had been the core regulatory objection.
The Policy Shift That Made Resolution Possible
The FDA’s January wellness guidance provided the legal foundation for closing the case. The agency determined that blood pressure features embedded in consumer wearables fall outside device regulation when manufacturers market them for general wellness insight rather than diagnosis, treatment, or prevention of disease. This distinction matters significantly for a market where consumer health devices increasingly incorporate features once exclusive to clinical settings.
Whoop CEO Will Ahmed characterized the FDA closeout as a “major development” on LinkedIn, noting that the company could have simply removed the feature, but chose instead to argue for the validity of its science. Ahmed stated that Whoop looks forward to working with the FDA on regulated medical technologies the company plans to bring to market, suggesting the resolution may open pathways for future products that require formal device approval.
The case illustrates a recurring tension in medtech regulation: the FDA must balance protecting consumers from misleading health claims against enabling legitimate innovation in consumer wellness devices. Healthcare policy discussions increasingly center on access and innovation, and wearable oversight sits at that intersection. Regulators face pressure to move quickly enough that standards do not freeze outdated definitions while moving carefully enough to prevent unsubstantiated medical claims.
What The Resolution Means For The Wearable Market
The Whoop case may lower barriers for other wearable makers seeking to offer blood pressure and similar biometric features without seeking medical device clearance. Companies can now point to the FDA guidance and Whoop’s successful modification as a model for adding features that approach clinical territory while maintaining wellness positioning.
However, the resolution also sets expectations. Manufacturers will need to adjust labeling, UI design, and marketing language carefully. Simply measuring blood pressure is not sufficient; the presentation must clearly signal the feature is for informational wellness purposes, not diagnosis or monitoring of hypertension. This distinction, though conceptually simple, requires ongoing compliance vigilance.
The timing is significant. Consumer demand for continuous biometric monitoring has grown substantially, and major wearable platforms-including smartwatches and fitness trackers-compete partly on feature depth. The FDA guidance and Whoop closeout together remove a major regulatory roadblock that had discouraged some companies from pursuing blood pressure features. Whether other manufacturers now expedite launches of similar capabilities remains to be seen.
Whoop’s path also illustrates that companies willing to invest in FDA dialogue and modify products to address specific regulatory concerns can resolve enforcement actions without full feature removal. This outcome may encourage other wearable makers facing similar objections to engage in constructive negotiation rather than capitulating immediately.
Remaining Uncertainties And Next Steps
The closeout letter does not broadly exempt all blood pressure wearable features from FDA oversight. Each company will need to demonstrate that its specific implementation aligns with the wellness guidance principles. Marketing claims, feature descriptions, and intended use will still face scrutiny if they cross into medical device territory.
Whoop’s stated intention to pursue regulated medical technologies suggests the company sees value in both the consumer wellness market and formal device pathways for future products. This dual approach may become standard for larger wearable makers seeking both rapid market entry for wellness features and clinical credibility for regulated offerings.
The broader question-whether the FDA guidance will prove durable or face future challenges-remains open. As wearables become more sophisticated and their measurements more clinically relevant, regulators may need to revisit the wellness boundary. For now, Whoop’s successful resolution provides a case study in how enforcement actions can conclude when companies address specific regulatory concerns and the agency updates policy to match technological reality.
